Ian Cromwell

Ian Cromwell

UNVERIFIED PROFILE

Are you Ian Cromwell?   Register this Author

Register author
Ian Cromwell

Ian Cromwell

Publications by authors named "Ian Cromwell"

Are you Ian Cromwell?   Register this Author

5Publications

109Reads

44Profile Views

Cost-Effectiveness Analysis of Using Loss of Heterozygosity to Manage Premalignant Oral Dysplasia in British Columbia, Canada.

Oncologist 2016 09 11;21(9):1099-106. Epub 2016 Jul 11.

Department of Cancer Control Research, British Columbia Cancer Agency, Vancouver, British Columbia, Canada Department of Oral Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada Faculty of Dentistry, University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0433DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016061PMC
September 2016

'Real-world' health care priority setting using explicit decision criteria: a systematic review of the literature.

BMC Health Serv Res 2015 Apr 17;15:164. Epub 2015 Apr 17.

School of Population and Public Health, University of British Columbia, Vancouver, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12913-015-0814-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433097PMC
April 2015

Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada.

J Thorac Oncol 2014 Oct;9(10):1449-58

*The Canadian Centre for Applied Research in Cancer Control, and the British Columbia Cancer Agency, Vancouver, British Columbia, Canada; †The British Columbia Cancer Agency, Vancouver, British Columbia, Canada; ‡Brock University, St. Catherines, Ontario, Canada; §Cancer Care Ontario and the Juravinski Cancer Centre, Hamilton, Ontario, Canada; ‖University Health Network and Princess Margaret Cancer Centre, Toronto, Ontario, Canada; ¶The Canadian Centre for Applied Research in Cancer Control, the British Columbia Cancer Agency and School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada; #The University of British Columbia School of Population and Public Health, Vancouver, British Columbia, Canada; **Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada; ††The British Columbia Cancer Agency and The Canadian Centre for Applied Research in Cancer Control and the University of British Columbia, Vancouver, British Columbia, Canada; ‡‡Beatrice Hunter Cancer Research Institute and Dalhousie University, Halifax, Nova Scotia, Canada; §§The Vancouver General Hospital, Vancouver, British Columbia, Canada; ‖‖Fionna Stanley Hospital and Sir Charles Gairdner Hospital, Perth, Western Australia; ¶¶Université Laval, Québec, Canada; ##Vancouver General Hospital, The University of British Columbia, Vancouver, British Columbia, Canada; ***The Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada; †††Princess Margaret Cancer Centre, Toronto, Ontario, Canada; ‡‡‡University of Calgary, Foothills Medical Centre, Calgary, Alberta, Canada; §§§Foothills Medical Centre, Calgary, Alberta, Canada; ‖‖‖Memorial University, St. Johns, Newfoundland, Canada; ¶¶¶The Ottawa Hospital, Ottawa, Ontario, Canada; ###Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; ****The Vancouver General Hospital and The University of British Columbia, Vancouver, British

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000283DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165479PMC
October 2014

Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.

Lung Cancer 2012 Jun 9;76(3):472-7. Epub 2012 Jan 9.

Canadian Centre for Applied Research in Cancer Control (ARCC), Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2011.12.003DOI Listing
June 2012

Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer: a real-world cost-effectiveness analysis.

J Thorac Oncol 2011 Dec;6(12):2097-103

Canadian Centre for Applied Research in Cancer Control (ARCC), University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e31822f657aDOI Listing
December 2011